Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may guide breast cancer therapy, reducing chemo need

NCT ID NCT07366112

Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This phase 2 trial tests a personalized approach for early-stage, hormone receptor-positive breast cancer. Participants receive a combination of CDK4/6 inhibitors and endocrine therapy before surgery. A blood test (ctDNA) is used to monitor tumor DNA and may help decide if chemotherapy can be safely avoided. The study aims to see if this strategy improves outcomes and reduces unnecessary treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CDK4/6 inhibitor combined with endocrine therapy
What this could lead to
If successful, this could help personalize breast cancer treatment, potentially allowing some patients to avoid chemotherapy based on ctDNA results.
What could go wrong
This is an early phase 2 trial with only 158 participants, so results may not apply to all patients. The approach is complex and may not improve outcomes or reduce side effects as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTDNA MONITORING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTDNA MONITORING EARLY-STAGE BREAST CANCER HER2-NEGATIVE BREAST CANCER HIGH-RISK BREAST CANCER HORMONE RECEPTOR POSITIVE BREAST CANCER

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.